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of individuals acutely infected in adulthood will spontaneously 
seroconvert and lose HBsAg. Conversely, only 5% of infants 
infected at birth or during early childhood will lose HBsAg, the 
remainder developing CHB. The correct interpretation of HBV 
serology is summarised in Table  1 . 
 Individuals with CHB are likely to be asymptomatic and liver 
function tests are often normal. Therefore, serological testing is 
essential to determine the HBV status of an individual. Individuals 
who are HBsAg negative and hepatitis B core antibody (anti-HBc) 
positive have evidence of past exposure to HBV. Hepatitis B 
virus DNA should be checked in these individuals to exclude 
occult infection. Hepatitis B infection results in the presence 
of covalently closed circular DNA (cccDNA) in hepatocytes, 
regardless of whether either HBsAg or HBV DNA are detectable. 
cccDNA acts as a transcriptional template and can persist 
indefinitely; it is the formation of this minichromosome that is 
central to HBV reactivation (HBVr). 3,4 As such, the concept of past 
infection is something of a misnomer; patients who are HBsAg 
negative, anti-HBc positive and HBV DNA negative will be referred 
to as ‘anti-HBc positive’ and are considered to have resolved HBV 
infection. In practice, individuals with prior exposure to infection 
and undetectable HBV DNA require no specific management 
or monitoring unless immunosuppressed as a consequence of 
disease or specific therapies, when HBVr can potentially become 
a clinically significant entity. Hepatitis B virus reactivation can 
manifest as asymptomatic viraemia with or without perturbation 
in serum alanine aminotransferase (ALT); however, a subgroup of 
patients will develop severe liver injury with jaundice, liver failure 
or even death. 
 There is emerging evidence suggesting that the actual number 
of individuals presenting with HBVr following commencement 
of treatment with immunosuppressive agents is increasing. In 
the UK, this can be attributed to an increase in the prevalence of 
positive HBV serology in the population in tandem with a rise in 
the licensed clinical indications for potent immunosuppression, 
including, but not restricted to, malignancies, inflammatory bowel 
disease (IBD), autoimmune disorders and rheumatic disease, as 
well as to the emergence of new agents that appear to account for 
HBVr. 5–7 In view of this, all major medical and scientific societies, 
including the American Association for the Study of Liver Diseases 
(AASLD), American College of Rheumatology (ACR), American 
Gastroenterological Association (AGA), American Society of 
Clinical Oncology (ASCO), British Society for Rheumatology 
(BSR), Centers for Disease Control and Prevention (CDC), German 
Society of Haematology and Medical Oncology (DGHO), European 
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 Introduction 
 Hepatitis B virus (HBV) infection remains a major global 
healthcare challenge with approximately one-third of the 
worldwide population living with current or past infection. The 
prevalence of individuals in the UK with serological evidence of 
present or past infection is increasing, predominantly in urban 
areas, because of migration patterns. In London, 1% of women 
undergoing antenatal screening have been identified as being 
hepatitis B surface antigen (HBsAg) positive, with incidence rates 
as high as 2.8% in some areas. 1 
 Chronic hepatitis B (CHB) is classically described in distinct 
disease phases, depending on the host immune response to the 
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Association for the Study of the Liver (EASL), European Crohn’s 
and Colitis Organisation (ECCO), European Society for Medical 
Oncology (ESMO), have published guidance on the management 
of HBVr. However, there is still ambiguity regarding optimal 
management to prevent HBVr, particularly regarding patients 
with negative HBsAg but positive anti-HBc. NICE guidelines have 
highlighted the importance of further research to elucidate the 
factors driving HBVr and to identify better strategies to screen 
and manage patients with positive hepatitis B serology receiving 
immunosuppressive treatments. 8 
 In this review, we summarise the recent international 
recommendations to prevent HBVr and provide some suggestions 
based on a multidisciplinary approach for prevention of HBVr in 
the UK healthcare setting. 
 Screening 
 The risk of HBVr can be classified as high (>10%), moderate 
(1–10%) or low (<1%). Testing for HBV serology before initiating 
immunosuppressive medication is recommended by international 
societies across disciplines, yet is poorly performed. 9,10 Effective 
screening should include testing for HBsAg, anti-HBc and hepatitis 
B surface antibody (anti-HBs). If either HBsAg or anti-HBc is 
positive, testing for HBV DNA is mandated. 8,11 The rate of HBV 
DNA positivity in patients with isolated positive anti-HBc serology 
has been estimated to be between 1.7% and 41%. 12 Even in 
individuals with negative HBsAg and positive anti-HBs, cases 
are reported with detectable HBV DNA. Although this is less 
common than in those with isolated anti-HBc, it is important 
that all patients with anti-HBc positivity are screened for occult 
 Table 1.  Definition and interpretation of serological tests for hepatitis B virus 
 Markers  Clinical interpretation 
HBsAg Hallmark of infection; positive during early phase of acute infection, persistently positive in chronic infection
Anti-HBs Recovery from acute infection (or chronic); immunity following vaccination
HBeAg eAg positivity associated with high replicative state; presence of inflammation and/or fibrosis determines disease 
phase; eAg negativity reflects a change in disease phase and is usually associated with the emergence of anti-
HBe; viral mutations in precore and basal core promoter regions result in eAg-negative hepatitis
Anti-HBe Marker of eAg seroconversion associated with immune control in low viraemic states
Anti-HBc (IgM) Positive in acute infection; may be positive during reactivation of HBV
Anti-HBc (IgG) Exposure to infection and present in association with HBsAg in chronic infection; HBsAg-negative, anti-HBc-positive 
serology usually indicative of past exposure to virus; anti-HBs may /may not be positive; if anti-HBs negative, a 
false positive anti-HBc should be considered (eg after IVIG infusion); HBV DNA must be checked to exclude occult 
infection
 Tests  Clinical interpretation 
HBsAg (–)
Indicative of past infection and clinically relevant in the context of immune suppressionTotal anti-HBc (+)
Anti-HBs (+)
HBsAg (–)
Indicative of prior hepatitis B vaccinationTotal anti-HBc (–)
Anti-HBs (+)
HBsAg (+)










Number of potential clinical interpretations: (i) past HBV infection (ii) false-positive anti-HBc (iii) occult chronic 
hepatitis B if HBV DNA detectable (iv) resolving acute infection
Total anti-HBc (+)
Anti-HBs (–)
 Anti-HBs = hepatitis B surface antibody; anti-HBe = hepatitis B ‘e’ antibody; anti-HBc = hepatitis B core antibody; HBeAg = hepatitis B ‘e’ antigen; HBsAg = hepatitis 
B surface antigen; HBV = hepatitis B virus; IVIG = intravenous immunoglobulin 
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infection. 13 Paul  et al recently showed that patients with resolved 
HBV infection receiving chemotherapy for haematological 
malignancies without antiviral prophylaxis, are at a decreased 
risk of HBVr when they have positive anti-HBs. 14 More recently, 
the virological marker Hepatitis B core-related antigen (HBcrAg) 
was reported to be associated with an increased risk of HBVr in 
HBsAg-negative and anti-HBc-positive subjects undergoing high-
risk immunosuppressive regimens. 15 This test remains a research 
tool and is not routinely used in clinical practice. 
 Early screening for HBV markers enables timely initiation of 
antiviral prophylaxis or treatment where indicated and reduces 
the risk of liver failure and death secondary to HBV reactivation in 
patients receiving chemotherapy. 16 Similarly, it also prevents any 
delay in starting immune suppression while awaiting specialist input 
and/or additional investigations. Patients with positive serology, 
particularly those with isolated anti-HBc, can be offered repeat 
testing. 12 
 Individuals with negative serological markers who are likely 
to need immune suppression should be immunised against 
HBV and it is noteworthy that effective immunisation is more 
challenging in this context. The first dose of anti-HBV vaccine 
should be administered 1–2 weeks before the administration of 
treatment and higher doses may be required in patients who 
are immunocompromised. A minimum of three doses of vaccine 
administered at monthly intervals are required for effective 
immunisation in patients who are immunocompetent. ECCO 
recommends monitoring maintenance of anti-HBs in patients at 
risk every 1–2 years. 17,18 False positive testing for HBsAg can occur 
for 1–2 weeks following administration of the vaccine, because 
the assay can also detect surface antigen (sAg) in the vaccine 
preparation. 
Table  2 shows the guidance from international societies on 
screening for HBV before immune suppression. 
 Blood products and intravenous immunoglobulin 
 Transfusion of blood products or infusion of intravenous 
immunoglobulin (IVIG) can result in passive transmission of 
antibodies associated with HBV. This can lead to patients being 
falsely informed that there is evidence of past HBV or, more 
importantly, being considered for antiviral prophylaxis in the 
context of immunosuppression. Baseline anti-HBc should be 
measured early during the course of disease to avoid this scenario 
and, if negative, subsequent positive serology can be disregarded 
in the absence of ongoing risk of acquisition of HBV. Should liver 
function tests become deranged during the course of immune 
suppression, HBsAg should be retested, as in any other patient. 19 
 Management of patients who are HBsAg positive 
 Hepatitis B virus reactivation is more common in individuals 
who are HBsAg positive, as opposed to HBsAg negative, and is 
defined as an increase in viral load of at least 100-fold. This may 
be associated with a transaminitis and, in some cases, will lead to 
acute liver failure. Patients who are positive for HBsAg should be 
referred to a clinician with experience in managing CHB, regardless 
of whether immunosuppressive therapy is planned or the level of 
HBV DNA. 
 If immune suppression is planned, patients who are HBsAg 
positive should start prophylaxis treatment with nucleos(t)ide 
therapy, namely tenofovir disoproxil fumarate (TDF) or entecavir 
(ETV), regardless of pretreatment disease activity. The recently 
licensed tenofovir alafenamide (TAF) may be indicated if there 
are renal concerns or prior exposure to lamivudine (or virological 
relapse on entecavir therapy). 11,17 , 20–23 
 This is the consensus approach from most international 
societies, with the exception of AGA. AGA exempts from 
this HBsAg-positive patients considered to be at a low risk 
of HBVr (<1%), who do not meet standard indications for 
antiviral treatment. Such groups might include those treated 
with traditional immunosuppressive agents (eg azathioprine, 
6-Mercaptopurine (6MP) or methotrexate), patients treated 
with intra-articular corticosteroids and those treated with any 
dose of oral corticosteroids daily for 1 week. 20 This may be a 
reasonable approach in the context of short courses of steroids 
or intra-articular treatment. However, in the context of long-term 
immunosuppression with azathioprine, 6MP and/or methotrexate, 
we support the view of EASL that patients who are HBsAg positive 
should be offered antiviral prophylaxis, particularly if it is likely 
that escalation to biologic therapies will be required in the future. 
Lamivudine should not be used in this group of patients because 
of the increased risk of viral resistance. NICE guidelines from 2013 
recommend the use of lamivudine as prophylaxis in patients with 
HBV DNA <2,000 IU/mL. 8 However, generic formulations of ETV 
and TDF are now available as cost-effective alternatives and 
 Table 2.  Guidelines on screening for hepatitis 
B virus markers before immunosuppression or 
chemotherapy 
 Society  Who should be 
screened? 
 Screening tests 
 AGA Patients at moderate 
or high risk of HBVr
HBsAg, anti-HBc + HBV DNA in 
case of positive results
 ASCO Groups at heightened 
risk for chronic HBV 
infection or if highly 
immunosuppressive 
treatment is planned
HBsAg+- anti-HBc in some 
populations




HBsAg, anti-HBc, and anti-HBs
 DGHO Groups at heightened 
risk
HBsAg, anti-HBc + HBV DNA in 
case of positive results
 ECCO All IBD patients at 
diagnosis
HBsAg, anti-HBc, and anti-HBs 
+ HBV DNA in case of positive 
results
 EASL All candidates for 
chemotherapy and 
immunosuppression
HBsAg, anti-HBc, and anti-HBs 
+HBV DNA in case of positive 
results
 AGA = American Gastroenterological Association; anti-HBc = hepatitis B core 
antibody; anti-HBs = hepatitis B surface antibody; ASCO = American Society 
of Clinical Oncology; CDC = Centers for Disease Control and Prevention; 
DGHO = German Society for Haematology and Medical Oncology; EASL = 
European Association for the Study of the Liver; ECCO = European Crohn´s 
and Colitis Organisation; HBsAg = hepatitis B surface antigen; HBV = hepatitis 
B virus; HBV DNA = hepatitis B virus DNA; HBVr = hepatitis B reactivation; IBD 
= inflammatory bowel disease 
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so there is no real barrier to prescribing these drugs as first-line 
agents in this setting. 
 EASL advise that antiviral treatment should be continued for 
at least 12 months after the cessation of immune suppression 
(18 months in the case of rituximab). This protracted course of 
antiviral prophylaxis is warranted because HBVr has been reported 
many months after the cessation of rituximab. This represents a 
shift in practice compared with guidance issued by NICE in 2013 
that recommended just 6 months of prophylaxis after cessation 
of immunosuppression. 8 Liver function tests and HBV DNA should 
be tested every 3–6 months during prophylaxis. 11 Patients with 
baseline HBV DNA levels above the treatment threshold (>2,000 
IU/mL) should continue antiviral treatment until endpoints 
applicable to patients who are immunocompetent are reached. 17 
 We recommend that cases should be discussed in a 
multidisciplinary setting before starting antiviral treatment. 
Long-term follow-up and monitoring of HBV markers should be 
conducted through specialist clinics. 
 Management of patients with evidence of past 
exposure to HBV (HBsAg negative and/or anti-HBc 
positive) 
 Patients in this group should be tested for HBV DNA and, if 
detected, should be managed as though they are HBsAg positive 
(see above). 11 Patients who are HBsAg negative, anti-HBc positive 
and DNA negative are referred to as ‘anti-HBc positive’ and are 
considered to have resolved HBV infection. 
 Patients who are anti-HBc positive will be at variable risk of 
HBVr depending upon host factors, including age and sex, the 
underlying condition for which immunosuppression is indicated, 
and the immunosuppressive regimen planned. There is more 
uncertainty over the management of this group than over those 
who are HBsAg positive because HBVr rates are variable. Titres of 
anti-HBs >100 IU/mL have been associated with lower rates of 
HBVr in patients treated with rituximab for lymphoma, 24 as have 
low titres of anti-HBc. 25 At present, none of the main international 
societies recommend withholding antiviral prophylaxis during 
rituximab on the basis of thresholds of serological titres for either 
anti-HBs or anti-HBc. 
 The underlying disease appears to have an important role in HBVr 
risk. Non-Hodgkin’s lymphomas (NHL) are the haematological 
malignancies most commonly associated with viral reactivation. 26 
In a multivariate analysis, acute lymphoid leukaemia (ALL) and 
multiple myeloma were also found to be independent risk factors 
for HBVr in patients who were anti-HBc positive. 27 
 Risk can be stratified based upon the drug regimen to be 
used. In 2013, rituximab received a box warning from the US 
Food and Drug Administration (FDA) regarding the risk of HBV 
reactivation. 28 Similarly, the European Medicine Agency (EMA) 
added a special warning for the BCR-ABL tyrosine kinase inhibitors 
(imatinib, bosutinib, dasatinib, nilotinib and ponatinib); their use 
in patients with positive HBV serology is also associated with the 
possibility of HBVr (EMA pharmacovigilance). 
 Risk assessment based on immune suppression regimens can be 
categorised as shown in Table  3 . 
 High risk (>10%) 
 Rituximab and other B-cell depleting therapies pose a particular 
risk for HBVr and all patients with active or past exposure 
to hepatitis B infection should receive antiviral prophylaxis. 
We recommend that ETV/TDF is used first line for antiviral 
prophylaxis in patients who are anti-HBc positive. Prophylaxis 
should continue throughout rituximab treatment and for at 
least 18 months afterwards (and indefinitely in those with 
ongoing immunosuppression as a result of active haematological 
malignancy). 29 Monitoring for reactivation should continue for a 
further 12 months after the cessation of antiviral prophylaxis. 11 
Recently, the PREBLIN study, a randomised prospective study, 
demonstrated a trend suggesting a prophylactic effect of TDF in 
preventing HBVr in patients receiving rituximab-based regimens 
for haematological malignancies. 30 
 Haematopoietic stem cell transplantation (HSCT), in particular 
allogeneic HSCT, is associated with a significantly increased risk of 
HBVr, with the highest rate (>50%) reported in patients who are 
HBsAg positive. 31 Patients who are anti-HBc positive are also at risk 
of HBVr, reported to be as high as 20%. 32 Rituximab, the number 
of chemotherapy cycles, as well as low anti-HBs levels were all 
reported to be risk factors for HBVr. 33 Of note, in such patients, the 
risk of seroreversion can persist for years. 34 
 Moderate risk (1–10%) 
 Table  3 shows drugs deemed to be of medium risk of HBVr. EASL 
advises that patients who are anti-HBc positive can receive 
medium risk immunosuppression with careful monitoring and 
pre-emptive therapy. Their recommendation is that HBsAg and/
or HBV DNA should be monitored every 1–3 months during and 
after immunosuppressive therapy; antiviral treatment should be 
initiated if either is positive. 11 
 A recent comprehensive review suggested that patients 
who are anti-HBc positive can be appropriately managed 
during immunosuppression with either monitoring or antiviral 
prophylaxis. 3 The guidance from international societies varies 
on this issue, with some in favour of initiating antiviral treatment 
in patients on immunosuppressive treatment only in the 
event of detectable HBV DNA or elevated aminotransferases. 
AASLD considers that, in patients who are anti-HBc positive, 
reactivation is infrequent and, hence, they should be monitored, 
and antiviral therapy only initiated upon HBVr occurrence. 22,23 
ECCO also recommends against routine prophylaxis and suggests 
monitoring of HBV DNA and ALT/aspartate aminotransferase 
(AST), taking into consideration the fact that HBVr of patients 
who are anti-HBc positive rarely occurs during the treatment 
of IBD. 17 
 The inhibition of tumour necrosis factor (TNF)-α signalling could 
lead to increased HBV replication and, hence, reactivation of the 
virus. Anti-TNF-α agents (eg infliximab, adalimumab, certolizumab, 
golimumab and etanercept) are widely used to treat patients with 
rheumatic disease, IBD and psoriasis, among other conditions, 
and have been implicated in HBVr; the estimated risk of viral 
reactivation with anti-TNF-α monotherapy varied in different 
studies from 1% to 10% for individuals who were HBsAg positive 
and was significantly lower in patients who were anti-HBc positive. 
It is still unclear whether the risk of HBVr varies between the anti-
TNF-α agents. 7 , 35–37 In a meta-analysis of patients treated with 
anti-TNF-α for rheumatic diseases, patients who were anti-HBc 
positive had a HBVr rate of 1.7%, while a study of patients who 
were HBsAg positive reported HBVr in 12.3% of patients. 38,39 The 
risk of HBVr with novel agents, such as ustekinumab, natalizumab, 
alemtuzumab and vedolizumab, remains unclear. 5,37 
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 Low risk (1%) 
 Patients on immune suppressive regimens with low risk of HBVr 
generally only require monitoring as outlined above. If there 
is likely to be treatment escalation, a prolonged duration of 
immunosuppression, or the underlying disease predisposes to 
immune suppression, then antiviral prophylaxis may be appropriate. 
 Steroids 
 Prednisolone constitutes an independent risk factor for HBVr when 
used as a monotherapy or, more importantly, when combined 
with other immunosuppressive medications. 35 All professional 
international societies suggest that, when a patient is due to be 
immunosuppressed with corticosteroids, an appropriate level 
of risk stratification should be undertaken, because it has been 
shown that the immunosuppressive effect of steroids is dose and 
duration dependent. 40 Guidelines from both DGHO and AGA in 
2015 highlight the high risk of HBVr (10%) in patients who are 
HBsAg positive treated with moderate- (prednisolone 10–20 mg 
or equivalent) or high-dose (prednisolone >20 mg or equivalent) 
corticosteroids for ≥4 weeks. 
 The following groups are deemed to be at moderate risk (1–10%) 
of HBVr during treatment with steroids: patients who are HBsAg 
positive treated with low-dose (prednisolone <10 mg daily or 
equivalent) corticosteroids for ≥ 4 weeks, and patients who are 
anti-HBc positive treated with moderate- (prednisolone 10–20 mg 
daily or equivalent) or high-dose (prednisolone >20 mg daily or 
equivalent) corticosteroids daily for ≥ 4 weeks. 
 Patients at low risk (<1%) of HBVr include those treated with 
intra-articular corticosteroids or a course of steroids lasting less 
than a week at any dose. 20,21 
 Practical considerations 
 Data from UK practice demonstrate that the introduction of local 
policies and raising awareness of the risk of HBVr can significantly 
improve the uptake of screening before starting rituximab. 9 Audits 
of local practice will help inform whether guidance is being adhered 
to and to ascertain the local prevalence of at-risk patients to 
inform resource allocation. For high-risk immunosuppression, such 
as rituximab, it would be prudent to introduce checkpoints within 
pharmacies and on infusion units to ensure that HBV serology has 
been checked before drug dispensing and/or administration. 
 Table 3.  Risk of hepatitis B virus reactivation stratified by immunosuppressive regimen 
  HBsAg positive  HBsAg negative – anti-HBc positive 
High risk >10% >  B-cell depleting agents (eg rituximab, ofatumumab)
>  Anthracycline derivatives (eg doxorubicin, epirubicin)
>  Moderate (prednisolone 10–20 mg daily or 
equivalent) or high-dose (prednisolone >20 mg daily 
or equivalent) corticosteroids daily for ≥4 weeks
>  Potent TNF-α inhibitors, including adalimumab, 
certolizumab, infliximab and golimumab
>  Local treatment for HCC, including TACE
>  B-cell depleting agents (eg rituximab, ofatumumab)
Moderate risk 
1-10%
>  Less potent TNF-α inhibitors (eg etanercept)
>  Cytokine or integrin inhibitors (eg abatacept, 
ustekinumab, natalizumab, vedolizumab)
>  Tyrosine kinase inhibitors (eg imatinib, nilotinib)
>  Immunophilin inhibitors, including cyclosporine
>  Proteasome inhibitors, such as bortezomib
>  HDIs
>  Low-dose (prednisolone <10 mg daily or equivalent) 
corticosteroids for duration of ≥4 weeks
>  Systemic chemotherapy
>  TNF-α inhibitors (eg etanercept, adalimumab, 
certolizumab, infliximab)
>  Cytokinee or integrin inhibitors (eg abatacept, 
ustekinumab, natalizumab, vedolizumab)
>  Tyrosine kinase inhibitors (eg imatinib, nilotinib)
>  Moderate (prednisolone 10–20 mg daily or equivalent) 
or high-dose (prednisolone >20 mg daily or equivalent) 
corticosteroids daily for ≥4 weeks 
>  Anthracycline derivatives (eg doxorubicin, epirubicin)
>  Immunophilin inhibitors, including cyclosporine
>  Proteasome inhibitors, such as bortezomib
>  HDIs
>  Systematic chemotherapy, including HCC
Low risk <1% >  Traditional immunosuppressive agents (eg 
azathioprine, 6-Mercaptopurine, methotrexate)
>  Traditional immunosuppressive agents (eg azathioprine, 
6-Mercaptopurine, methotrexate)
>  Intra-articular corticosteroids
>  Low-dose (prednisolone <10 mg or equivalent) 
corticosteroids for ≥4 weeks
>  Any dose of oral corticosteroids daily for <1 week
>  Intra-articular corticosteroids
>  Any dose of oral corticosteroids daily for <1 week
 Anti-HBc = hepatitis B core antibody; HBsAg = hepatitis B surface antigen; HBVr = hepatitis B virus reactivation; HCC = hepatocellular carcinoma; HDIs = histone 
deacetylase inhibitors; TACE = transarterial chemoembolization; TNF = tumour necrosis factor 
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 More evidence is needed to facilitate decisions of whether 
to initiate monitoring or prophylaxis in the medium-risk group. 
Factors that may favour prophylaxis over monitoring alone 
are: patient age (or generally physiologically frail), male sex, 
haematological malignancy, treatment with more than one 
low-to-medium-risk immunosuppressive agent, or a reasonable 
likelihood of treatment escalation. If monitoring is chosen, then 
consideration needs to be given to how this will be delivered in 
clinical practice and who is the responsible physician. 
 In situations where monitoring cannot be offered reliably in the 
moderate-risk group, then antiviral prophylaxis might be a more 
appropriate and pragmatic approach. ETV and TDF are considered 
safe and well tolerated and the emergence of generic formulations 
in the UK make this a cost-effective option. The wishes of the 
patient should also be considered in this situation. 
 In our experience, antiviral treatment and monitoring during 
immune suppression can be safely delivered by specialist nurses 
with experience in managing HBV. However, we recommend that 
all patients with positive HBV serology should be discussed in a 
multidisciplinary setting under the guidance of a physician with 
an interest in HBV before the initiation of immunosuppression and 
management in a nurse-led clinic. 
 A multidisciplinary model could be developed as shown in Fig  1 
to help identify areas where increased resources might be required 
and referral pathways streamlined. 
 Conclusion 
 HBVr is likely to be of increasing clinical significance as potent 
immunosuppressive regimens are used more widely across all 
medical specialties and, as such, should be managed using a 
multidisciplinary approach. HBVr will be of particular importance 
in clinical practice where the population served includes migrants 
from endemic areas, and treating physicians should be aware of the 
potential risk for patients with resolved HBV infection. In an era of 
safe and inexpensive potent antivirals, there is now a paradigm shift 
to offer antiviral prophylaxis to more patients who are at risk of HBVr 
and to extend the duration of both prophylaxis and subsequent 
monitoring. Further research to improve risk stratification is required, 
including the evaluation of novel virological markers, such as 
HBcrAg, as well as anti-HBc and anti-HBs titres and their potential 
utility in clinical practice. ■ 
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